Anti-Angina Medication Management

First-Line Therapies

The European Society of Cardiology recommends beta-blockers as a first-line treatment for angina, which reduce myocardial oxygen demand by decreasing heart rate, contractility, and blood pressure, and are particularly beneficial in patients with prior myocardial infarction or heart failure 1
The European Society of Cardiology suggests that calcium channel blockers, such as dihydropyridines (amlodipine, nifedipine) and non-dihydropyridines (verapamil, diltiazem), reduce myocardial demand by decreasing afterload and enhance oxygen supply through coronary vasodilation, and are particularly effective for vasospastic angina 2
The American Heart Association recommends nitrates, which work through venodilatation, reduced cardiac filling pressures, and coronary vasodilation, and require a daily "nitrate-free" interval (10-12 hours) to prevent tolerance 3

The European Society of Cardiology recommends ranolazine as a second-line treatment for angina, which reduces angina frequency and nitroglycerin use when added to standard therapy, and is particularly useful in patients with low heart rate and/or blood pressure 4
The European Society of Cardiology suggests that ivabradine, a selective sinus node inhibitor, reduces heart rate and is an alternative for patients with beta-blocker intolerance 5
The American College of Cardiology recommends nicorandil, a potassium channel activator with nitrate-like effects, which is useful for vasospastic angina and as add-on therapy 1
The European Society of Cardiology recommends trimetazidine, a metabolic agent that improves cardiac metabolism, which is particularly beneficial in patients with microvascular angina 6

The European Society of Cardiology recommends starting with short-acting nitrates for immediate symptom relief, and initial treatment with beta-blockers and/or calcium channel blockers is recommended for most patients 1
The American Heart Association suggests that combination therapy, such as a beta-blocker with a dihydropyridine calcium channel blocker, is often required for adequate symptom control 1
The European Society of Cardiology recommends selection of therapy tailored to specific patient characteristics, such as vasospastic angina, microvascular angina, peripheral artery disease, and AV conduction defects 7

The European Society of Cardiology notes that no anti-anginal medication has been proven to improve long-term cardiovascular outcomes, except beta-blockers when given within 1 year after acute myocardial infarction 8
The American College of Cardiology emphasizes that adherence to medication is crucial for successful angina management 5

The European Society of Cardiology recommends prescribing sublingual nitroglycerin for all patients to use as needed for acute angina episodes and before activities known to trigger symptoms 9, 10
If sublingual preparations are ineffective, consider buccal formulations, as suggested by the British Medical Journal 11

The British Medical Journal suggests aspirin 75-300 mg daily for all patients unless contraindicated 11

The European Society of Cardiology recommends starting with a beta-1 selective blocker and titrating to full dose before adding other agents 9, 10
Never discontinue beta-blockers abruptly in patients with coronary artery disease—taper over 1-2 weeks to avoid severe exacerbation of angina, MI, or ventricular arrhythmias, as advised by the British Medical Journal 11

The European Society of Cardiology suggests switching to calcium channel blocker monotherapy if beta-blockers are intolerant or contraindicated 9, 10
Consider long-acting nitrates, nicorandil, or ivabradine as alternative first-line options if beta-blockers are not tolerated 9, 10

The British Medical Journal recommends referring patients to cardiology for angiography if symptoms remain uncontrolled on full doses of two drugs 11

The European Society of Cardiology recommends initiating Vastarel (trimetazidine) as second-line add-on therapy when angina symptoms remain inadequately controlled despite optimal first-line treatment with beta-blockers and/or calcium channel blockers 12, 13
Beta-blockers and/or calcium channel blockers are the recommended first-line antianginal agents and should be titrated to optimal doses before considering trimetazidine 14, 12, 13

Target heart rate of 55-60 beats per minute with beta-blockers when used for antianginal purposes 12
All patients should receive short-acting nitrates for immediate symptom relief regardless of other therapy 14
Trimetazidine should be added when angina frequency remains unacceptable despite optimal doses of beta-blockers and/or calcium channel blockers 15, 16, 13
Patients with low blood pressure (systolic <130 mmHg, diastolic <80 mmHg) may benefit from trimetazidine as it does not impair coronary perfusion 17

Heart failure with reduced ejection fraction (HFrEF): Trimetazidine can be added to beta-blockers for additional angina control without negative hemodynamic effects 12, 13, 17
Microvascular angina: Trimetazidine is particularly beneficial in this subgroup 12
The American Heart Association and European Society of Cardiology suggest that trimetazidine works through metabolic modulation, making it complementary to first-line agents 15, 16

No proven mortality benefit: Unlike beta-blockers post-MI, trimetazidine has not been shown to reduce cardiovascular death or myocardial infarction 12, 13
Should not replace prognostic medications (aspirin, statins, ACE inhibitors) 14
Do not use trimetazidine as monotherapy for initial angina management 15, 16
Optimize dosing of one drug before adding another; avoid premature triple therapy 15, 16